[go: up one dir, main page]

NO953321L - 2,3 cyklisk kondenserte 1,4-dihydropyridiner, fremgangsmåte for fremstilling derav og deres anvendelse som legemidler - Google Patents

2,3 cyklisk kondenserte 1,4-dihydropyridiner, fremgangsmåte for fremstilling derav og deres anvendelse som legemidler

Info

Publication number
NO953321L
NO953321L NO953321A NO953321A NO953321L NO 953321 L NO953321 L NO 953321L NO 953321 A NO953321 A NO 953321A NO 953321 A NO953321 A NO 953321A NO 953321 L NO953321 L NO 953321L
Authority
NO
Norway
Prior art keywords
carbon atoms
dihydropyridines
drugs
preparation
cyclic condensed
Prior art date
Application number
NO953321A
Other languages
English (en)
Other versions
NO953321D0 (no
Inventor
Klaus Urbahns
Siegfried Goldmann
Hans-Georg Heine
Bodo Junge
Rudolf Schone-Loop
Henning Sommermeyer
Thomas Glaser
Reilinde Wittka
Jean-Marie-Viktor De Vry
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO953321D0 publication Critical patent/NO953321D0/no
Publication of NO953321L publication Critical patent/NO953321L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet nye 2,3-cyklisk kondenserte 1,4-dihydropyridiner med generell formel (I),. hvori R står for aryl med 6 til 10 karbonatomer eller pyrldyl, som eventuelt er substituert Inntil 5 ganger, likt eller forskjellig, med cyano, halogen, trifluormetyl eller med rettkjedet eller forgrenet alkyltlo med Inntil 6 karbonatomer , Rstår for hydrogen eller for rettkjedet eller forgrenet alkyl med Inntil 8 karbonatomer, Rstår for rettkjedet eller forgrenet alkyl med inntil 6 karbonatomer, eller for cykloalkyl med 3 til 6 karbonatomer, D og E står sammen for en to-verdig rest med formelen -C0-CH2-C(CH3 )2-CH2-, -C0-0-CH- eller. -CH-0-C0-. og salter derav.Det er videre beskrevet fremgangsmåter for fremstilling av forbindelsene og deres anvendelse som legemidler, fortrinnsvis for behandling av det sentrale nerve-systemet .
NO953321A 1994-08-25 1995-08-24 2,3 cyklisk kondenserte 1,4-dihydropyridiner, fremgangsmåte for fremstilling derav og deres anvendelse som legemidler NO953321L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4430092A DE4430092A1 (de) 1994-08-25 1994-08-25 2,3-Cyclisch kondensierte 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
NO953321D0 NO953321D0 (no) 1995-08-24
NO953321L true NO953321L (no) 1996-02-26

Family

ID=6526497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953321A NO953321L (no) 1994-08-25 1995-08-24 2,3 cyklisk kondenserte 1,4-dihydropyridiner, fremgangsmåte for fremstilling derav og deres anvendelse som legemidler

Country Status (15)

Country Link
US (1) US6121284A (no)
EP (1) EP0705830A1 (no)
JP (1) JPH0859622A (no)
KR (1) KR960007594A (no)
CN (1) CN1127250A (no)
AU (1) AU3011095A (no)
CA (1) CA2156672A1 (no)
CZ (1) CZ217495A3 (no)
DE (1) DE4430092A1 (no)
FI (1) FI953956A (no)
HU (1) HU218209B (no)
IL (1) IL115029A0 (no)
NO (1) NO953321L (no)
PL (1) PL310147A1 (no)
SK (1) SK104495A3 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
JP2002528452A (ja) * 1998-10-28 2002-09-03 アボット・ラボラトリーズ ジヒドロピリジン化合物および使用方法
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
EP1259510B1 (en) * 2000-03-03 2004-06-02 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20050075359A1 (en) * 2003-03-14 2005-04-07 Rikako Kono Large conductance calcium-activated K channel opener
EP1663227A2 (en) * 2003-09-10 2006-06-07 Synta Pharmaceuticals Corporation Dihydropyridine compounds for treating or preventing metabolic disorders
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
JP2008540549A (ja) * 2005-05-09 2008-11-20 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能調節用化合物
WO2010033643A2 (en) * 2008-09-17 2010-03-25 Burnham Institute For Medical Research Small molecule compounds for stem cell differentiation
US9233926B2 (en) * 2008-09-17 2016-01-12 Sanford-Burnham Medical Research Institute Compounds for stem cell differentiation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003148A1 (de) 1970-01-24 1971-07-29 Bayer Ag Neue 1,4-Dihydropyridinderivate
GB1430961A (en) 1972-01-22 1976-04-07 Yamanouchi Pharma Co Ltd 1-substituted-1,4-dihyddrypyridine derivatives
US4021434A (en) * 1972-01-22 1977-05-03 Yamanouchi Pharmaceutical Co., Ltd. Sodium β-[2,6-dimethyl-3,5-bis(ethoxycarbonyl)-4-(3-nitrophenyl)-1,4-dihydropyridine-1-yl]ethyl sulfate
DE3410645A1 (de) * 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3443678A1 (de) * 1984-11-30 1986-06-05 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 4-acyloxy-3-oxo-buttersaeureestern
DE3521761A1 (de) * 1985-06-19 1987-01-02 Bayer Ag Neue 1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4125271A1 (de) * 1991-07-31 1993-02-11 Bayer Ag Neue n-alkylierte 1,4-dihydropyridindicarbonsaeureester

Also Published As

Publication number Publication date
US6121284A (en) 2000-09-19
JPH0859622A (ja) 1996-03-05
HU218209B (hu) 2000-06-28
CZ217495A3 (en) 1996-03-13
CA2156672A1 (en) 1996-02-26
FI953956A0 (fi) 1995-08-23
CN1127250A (zh) 1996-07-24
AU3011095A (en) 1996-03-07
IL115029A0 (en) 1995-12-08
HUT74615A (en) 1997-01-28
DE4430092A1 (de) 1996-02-29
NO953321D0 (no) 1995-08-24
PL310147A1 (en) 1996-03-04
HU9502503D0 (en) 1995-10-30
EP0705830A1 (de) 1996-04-10
SK104495A3 (en) 1996-06-05
KR960007594A (ko) 1996-03-22
FI953956A (fi) 1996-02-26

Similar Documents

Publication Publication Date Title
BR8704582A (pt) Processo para preparar derivados de piridinacarboxamida
DE68906552D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
DK0487071T3 (da) Kondenserede heterocykliske forbindelser, deres fremstilling og anvendelse
PT87163A (pt) Process for preparing 1-phenyl-3-naphthalenyloxipropanamines
NO953321L (no) 2,3 cyklisk kondenserte 1,4-dihydropyridiner, fremgangsmåte for fremstilling derav og deres anvendelse som legemidler
NO161564C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-carbolin-3-oxadiazolylderivater.
ES2044981T3 (es) Un proceso para la preparacion de nuevos derivados de 4(3h)-quinazolinona.
DK26289D0 (da) Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse
DK240184D0 (da) Beta-carboline-3-carboxylic acid derivatives and method of preparing the same
ES546602A0 (es) Un procedimiento para producir un derivado de 2-(3,5-dial- quil-4-hidroxifenil)indol
NO167925C (no) Faste polymere hydroksybenzofenon-forbindelser med stabiliseringsmiddelvirkning, fremgangsmaate for deres fremstilling og deres anvendelse som stabiliseringsmiddel for organiske polymerer
ATE140229T1 (de) Benzoxazepinon-verfahren
NO891381L (no) Fremgangsmaate for fremstilling av nye fluorfosfonatnukleotidderivater.
SE8802428D0 (sv) New compounds
NO862054L (no) Fremgangsmaate for fremstilling av nye berbanderivater.
DK0388081T3 (da) Middel til behandling af sygdomme i det cerebrale neurotransmissionssystem
NO171639C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolpyrazolderivater
FR2626279B1 (fr) Nouveaux derives de l'indolo(3,2,1-de)(1,4)-oxazino(2,3,4-ij)(1,5) naphthyridine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
WO2001035938A3 (de) Pharmakologisch aktive tetrahydrothiopyran-4-ol-derivate, verfahren zu ihrer herstellung und verwendung
ATE103467T1 (de) Chemische hybridisierung von dikotylen.
DE3781044D1 (de) Prophylaktische und heilende zusammensetzung enthaltende eine 8-chlorbenzothiazepin-verbindung und dessen verwendung.
BR0011798B1 (pt) processo para a preparação de compostos de condensação e usos dos referidos compostos.
ES2045335T3 (es) Un procedimiento para la preparacion de nuevas s-difluorometilhomocisteinas.